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Other names: LUCA-15; H37; G15 
Location: 3p21.3 
Note: 3p21.3 is a putative human lung cancer tumor 




The gene spans about 30.03 Kb. Orientation plus 
strand. At least 25 exons. 
Transcription 
Full length RBM5 has 3.1 Kb, 2448 bp open reading 
frame. The gene encodes a number of alternative splice 
variants, identified by reverse transcription polymerase 
chain reaction. One splice variant lacks exon 6, 
RBM5delta6. Three other RNA splice variants retain 
intronic sequences, RBM5+5+6 retains introns 5 and 6, 
RBM5+6 retains intron 6 and clone 26 which is a 
partial cDNA containing an open reading frame and 
terminates within intron 6. A 326 bp antisense cDNA 
that maps to the intronic region of RBM5, je2, has also 
been identified. Both, RBM5delta6 and clone 26 




RBM5/LUCA-15 splice variants. Boxes represent the exons, intronic sequences are represented by horizontal lines. The arrows point to 
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Protein 
Description 
Full length RBM5 encodes a protein with a molecular 
mass of about 90 kDa (815 amino acids). The protein 
has two RNA Binding Domains (RBD), also 
recognized as RNA Recognition Motif (RRM). RBM5 
structure also features other functional motifs, which 
includes two putative zinc-finger DNA binding motifs, 
two bipartite nuclear localisation signals and a G-patch 
domain (a conserved domain in eukaryotic RNA-
processing proteins and type D retroviral polyproteins), 
suggesting a role for RBM5/LUCA-15 in RNA 
processing. In addition, the C-terminal region of 
RBM5/LUCA-15 contains several domains including a 
glutamine rich domain (362-385), which is thought to 
serve as protein-protein interaction site in certain RNA- 
and DNA- binding proteins. 
RBM5delta6 encodes a protein of 17 kDa, due to a 
frameshift mutation caused by the deletion of exon 6. 
The only functional motif retained by this truncated 
protein is the arginine/glycine-rich amino terminal 
region. A putative 21 kDa is reported to be encoded by 
RBM5+5+6 and clone 26, as revealed by an in vitro 
transcription/translation study in rabbit reticulocyte 
lysate. 
Expression 
Full length RBM5 and its alternative splice variants 
RNA are widely expressed in both primary tissue and
cell lines. Northern blot analysis revealed higher 
expression in skeletal and heart muscles and pancres. 
The expression of the full length RBM5 mRNA is 
reported to be high in adult thymus and low in the 
foetal thymus, suggesting that its expression is 
developmentally regulated. Full length RBM5/LUCA-
15 is reported to be down-regulated in breast cancer 
specimens, in 82% of primary non-small-cell lung 
carcinoma specimens and in many lung cancer cell 
lines and in vestibular schwannomas (27 fold 
reduction). The expression of RBM5delta6 RNA is 
highest in transformed cells. The full length RBM5 
protein is ubiquitously expressed in human tissues. It 
was found to be downregulated in 73% of primary non-
small-cell lung carcinoma specimens compared to 
normal adjacent tissue. RBM5/LUCA-15 was one of 
the antigens identified by autologous antibody in 
patients with renal carcinoma. Overexpression of je2,
the 326 bp antisense sequence, resulted in the 
downregulation of the RBM5 protein (95 kDa) and the
upregulation of the 17 kDa protein (RBM5delta6). 
Localisation 
RBM5 protein includes bipartite nuclear localisation 
signals suggesting its localisation to the nucleus. 
Function 
RBM5/LUCA-15 is among the 35 genes located within 
the 370 kb overlapping lung cancer homozygous 
deletion region at 3p21.3. RBM5 has been implicated 
in the control of cell death by apoptosis and cell 
proliferation. RBM5's involvement in apoptosis and 
malignancy has been the focus of many recent studies, 
with all results converging on a role for RBM5/LUCA-
15 as a Tumor Suppressor Gene (TSG). RBM5 splice 
variants have been shown to function as regulators of 
apoptosis. Stable expression of Je2, in human T-cell 
lines CEM-C7 and Jurkat produced marked inhibition 
of Fas-mediated apoptosis and conferred protection 
from apoptosis induced by other stimuli. RBM5delta6 
inhibits CD95-mediated apoptosis as well as 
accelerating cell proliferation. 
Overexpression of the full length RBM5 in CEM-C7 
and Jurkat T-cell lines suppressed cell proliferation 
both by inducing apoptosis and by inducing cell cycle 
arrest in G1. Consistently, RBM5/LUCA-15 
overexpression also inhibited human lung cancer cell 
growth (A549 non-small cell lung cancer line) by 
increasing apoptosis and inducing cell cycle arrest in 
G1. This inhibition of cell growth was reported to be
associated with decreased cyclin A and phosphorylated 
RB and an increase in the level of the proapototic 
protein Bax. Introducing RBM5/LUCA-15 into breast 
cancer cells that had 3p21-22 deletions reduced both
anchorage-dependent and anchorage-independent 
growth. RBM5/LUCA-15 also is reported to suppress 
anchorage-dependent and anchorage-independent 
growth in A9 mouse fibrosarcoma cells and to inhibit 
their tumour forming activity in nude mice. 
RBM5/LUCA-15 was one of the nine genes down-
regulated in metastasis and it has been included in the 
17 common gene signature associated with metastasis 
identified in multiple solid tumour types. Solid tumours 
carrying this gene expression signature had high rates 
of metastasis and poor clinical outcome. Microarray-
based analysis of changes in gene expression caused by 
the modulation of the level of RBM5/LUCA-15 were 
carried out. Among 5603 genes on cDNA microarray, 
35 genes, well known for their roles in the cell cycle as 
well as in apoptosis, were found to be differentially 
expressed as a result of RBM5/LUCA-15 
overexpression in CEM-C7 cells. 
These RBM5/LUCA-15 modulated genes include a 
number of cyclin-dependent kinase complexes, most 
notably CDK2 and three putative oncogenes which are 
down-regulated by RBM5/LUCA-15. These are Pim-1, 
a serine/threonine kinase, ITPA (inosine triphosphate 
pyrophosphatase) and Amplified in Breast cancer 1 
(AIB1). Other functionally important genes modulated 
by RBM5/LUCA-15 are well established to play 
specific anti apoptotic roles such as BIRC4 (AIP3), 
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BIRC3 (cIAP2, MIHC), Mcl-1, a member of the Bcl-2 
family of apoptosis suppressors, and TRAF1, 
supporting a role for RBM5/LUCA-15 in apoptosis. 
Other genes upregulated by RBM5/LUCA-15 include 
Stat5b, Annexin I and Bone Morphogenetic Protein 5 
(BMP5), implicated in apoptosis, immunosuppression 
and organ development respectively. 
Homology 
RBM5 shares 30% amino acid sequence homology 
with its immediate telomeric neighbor, the putative 
tumor suppressor gene RBM6. Another RNA Binding 
Motif protein that shares high homology with RBM5 
(53% at the amino acid level) is RBM10. The RBM10 
gene is located on the X chromosome at p11.23. No 
function has yet been determined for RBM10. The 
mouse RBM5 gene is 90% identical on cDNA level 
and 97% on protein level. The fly proteome contain 
three similar proteins, of which CG4887 gene product 
shows 43% similarity. The rat binding protein S1-1 has 
similar domain structure and is close in amino acid 
sequence to RBM5. 
Mutations 
Note: Mutations in the RMB5 gene have not been 
found in lung cancer. RBM5 is reported to be 
downregulated in RAS-transformed Rat-1 cells, in 
samples from breast cancer, in human schwannomas 
and in about 75% of primary lung cancers specimens. 
RBM5 was one of the nine genes down-regulated in 
metastasis in primary tumors and it has been included 
in the 17 common gene signature associated with 
metastasis identified in multiple solid tumour types. 
Solid tumours carrying this gene expression signature 
had high rates of metastasis and poor clinical outcomes. 
Implicated in 
Lung cancer and many other cancers 
Disease 
RBM5 is located at the human chromosomal locus 
3p21.3, which is strongly associated with lung cancer 
and many other cancers, including head and neck, 
renal, breast and female genital tract. More than 90% of 
freshly microdissected primary lung cancers display 
loss of heterozygosity (LOH) of 3p21.3. RBM5 is 
implicated in apoptosis and in cell cycle regulation. 
Oncogenesis 
The ability of RBM5/LUCA-15 to inhibit the growth of 
transformed cells fulfils one of the criteria for a tumor 
suppressor. The simultaneous changes in proliferation 
and inhibition of apoptosis brought about by 
dysregulation of the RBM5/LUCA-15 locus are likely 
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